Sm Drugs Private Limited
Founded in 2013 and headquartered in Tamil Nadu, India.
2013 | Madurai, Tamil Nadu (India) | Active
Sm Drugs Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
- Paid Up Capital ₹ 0.40 M
- Company Age 11 Year, 2 Months
- Last Filing with ROC 31 Mar 2018
- Open Charges ₹ 5.43 M
- Satisfied Charges ₹ 2.50 M
- Revenue Growth 57.78%
- Profit Growth -94.63%
- Ebitda 1407.48%
- Net Worth 0.10%
- Total Assets 315.65%
About Sm Drugs
Sm Drugs Private Limited (SDPL) is a Private Limited Indian Non-Government Company incorporated in India on 19 December 2013 and has a history of 11 years and two months. Its registered office is in Madurai, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2018. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 0.40 M.
The company currently has active open charges totaling ₹5.43 M. The company has closed loans amounting to ₹2.50 M, as per Ministry of Corporate Affairs (MCA) records.
Kanthimathinathan Kandasamy and Shanmugasundari serve as directors at the Company.
Company Details
- Location
Madurai, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51101TN2013PTC094223
- Company No.
094223
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Dec 2013
- Date of AGM
29 Sep 2018
- Date of Balance Sheet
31 Mar 2018
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Pharma
Who are the key members and board of directors at Sm Drugs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kanthimathinathan Kandasamy  | Director | 24-Nov-2015 | Current |
| Shanmugasundari | Director | 24-Nov-2015 | Current |
Financial Performance of Sm Drugs.
Sm Drugs Private Limited, for the financial year ended 2016, experienced significant growth in revenue, with a 57.78% increase. The company also saw a substantial fall in profitability, with a 94.63% decrease in profit. The company's net worth moved up by a moderate rise of 0.1%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sm Drugs?
In 2016, Sm Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
Open Charges
₹5.43 M
Satisfied Charges
₹2.50 M
Charges Breakdown by Lending Institutions
- The South Indian Bank Limited : 0.54 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 15 May 2019 | The South Indian Bank Limited | ₹5.43 M | Open |
| 01 Aug 2017 | Others | ₹2.50 M | Satisfied |
How Many Employees Work at Sm Drugs?
Unlock and access historical data on people associated with Sm Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sm Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sm Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
